The Rare Diseases Foundation is pleased to announce the signing of a partnership agreement with AG2R LA MONDIALE, a specialist in social and asset protection in France. This 24-month support will result in the financing of one of the Foundation's winning projects in Human and Social Sciences on "Accompanying parents faced with the diagnosis of permanent neonatal deafness".
This study is led by Dr. Barbara Le Driant of the University of Picardie Jules Verne (UPJV) in partnership with the University Hospital of Lille and associations of patients and families.
It concerns a concrete example of innovative research on the theme of parent helpers. It is a pilot study aiming to deepen the understanding of the experience of parents of newborn children diagnosed with neonatal deafness, with a view to developing proposals for early intervention. Although it is considered a rare disease affecting 1 in 1000 births, deafness detected at birth represents the most frequent sensory handicap. The experience of parents faced with this ordeal remains poorly documented and studies are needed to improve their support.
____________________________
"About AG2R LA MONDIALE:
A specialist in social and asset protection in France, AG2R LA MONDIALE insures individuals, companies and industries, to protect health, secure assets and income, guard against life's accidents and prepare for retirement. The Group has more than 15 million policyholders and supports 500,000 companies on a daily basis. With more than 11,000 employees, AG2R LA MONDIALE is present throughout France and its overseas territories. As a mutual insurance company governed by parity, the Group cultivates a unique social protection model that closely combines profitability and solidarity, performance and social commitment. Each year, it devotes several million euros to helping vulnerable people and supporting individual and collective initiatives.
Follow the news: www.ag2rlamondiale.fr / @AG2RLAMONDIALE "
Photos: Gilles Montagne, Head of Social Action Development Hauts-de-France and Pr Daniel Scherman, Director of the Rare Diseases Foundation